Updated Varian Brachytherapy Applicator Receives Clearance

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

Updated Varian Brachytherapy Applicator Receives Clearance

PALO ALTO, California—FDA has granted Varian Medical Systems 510K clearance to market its Esophagus Bougie Set, a brachytherapy applicator designed specifically for intraluminal treatment of esophageal cancer. According to Varian, the new technology allows optimal positioning of the applicator set in reference to the tissue being treated and can be used with Varian's full range of VariSoruce and GammaMed HDR afterloaders.

Articles in this issue
Curcumin Evaluated for the Treatment of Pancreatic Cancer
Tykerb Approved for Metastatic HER2+ Breast Cancer
'Male Lumpectomy' Via Focal Cryoablation Expands Treatment Options for Selected Prostate Cancer Patients
Drug for BPH May Also Reduce the Risk of Prostate Cancer
Phase III Trial of Prostvac-VF Is Launched
Electronic System Reminds Patients to Schedule Exams
Phase II Trial of Panzem for Renal Cell Carcinoma Initiated
Chemotherapy May Enrich Tumorigenic Cells in Breast Ca
Hand-Assisted Laparoscopic Technique May Reduce Surgery Time in Colon Cancer: New Study Is Underway
Watchful Waiting Management for Prostate Ca a Hard Sell
Once-Weekly SC Idraparinux Equals Standard DVT Rx
Patients Using Unapproved Cancer Agent
CT Lung Screens: No Lives Saved
Transgene Enrolls First Patients in Trial of TG 1042 in CBCL
FDA Updates Warning Labels of ESAs in Cancer Patients
Recent Videos
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
Related Content
Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Tim Cortese
January 9th 2025
Article

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

ODAC Votes Against PD-L1 as Efficacy Biomarker in Esophageal Cancers

ODAC Votes Against PD-L1 as Efficacy Biomarker in Esophageal Cancers

Russ Conroy
September 26th 2024
Article

Eleven votes were cast against the favorability of using anti–PD-1 inhibitors in patients with ESCC and a PD-L1 expression of less than 1.

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Kyle Doherty
Published: June 2nd 2024 | Updated: June 3rd 2024
Article

The combination of perioperative chemotherapy plus FLOT improved overall survival vs neoadjuvant chemoradiation in patients with resectable esophageal cancer.

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.

Setanaxib/Pembrolizumab Improves Survival in Head and Neck Cancer

Russ Conroy
May 8th 2024
Article

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.